Isobutyl-n-butyl-oxalat | 26404-34-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Isobutyl-n-butyl-oxalat
• 英文别名: Oxalic acid, butyl isobutyl ester；1-O-butyl 2-O-(2-methylpropyl) oxalate
• CAS: 26404-34-2
• 化学式: C₁₀H₁₈O₄
• 分子量: 202.251
• InChiKey: YYVHZJGLAAWCSL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  14
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Isobutyl-n-butyl-oxalat 在 五氯化磷 作用下， 生成 Dichlor-butyloxy-essigsaeure-isobutylester
  参考文献：
  名称：

  Ivashchenko,Ya.N.; Moshchitskii,S.D., Journal of general chemistry of the USSR, 1964, vol. 34, p. 610 - 613

  摘要：

  DOI：
• 作为产物：
  描述：

  异丁醇 、 草酸二丁酯 在 copper(l) chloride 作用下， 生成 Isobutyl-n-butyl-oxalat
  参考文献：
  名称：

  Ivashchenko,Ya.N.; Moshchitskii,S.D., Soviet progress in chemistry, 1969, vol. 35, # 11, p. 59 - 60

  摘要：

  DOI：

文献信息

• ALICYCLIC HETEROCYCLIC COMPOUND
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP1970373A1

  公开（公告）日：2008-09-17

  An alicyclic heterocyclic compound represented by the following formula or a pharmaceutically acceptable salt thereof: wherein ring A is a heterocyclic ring, ring B is a carbocyclic ring, a heterocyclic ring etc., P1 and P2 are CH or N, q and r are 0 to 2, X is -NH-, -O-, -CH2-, etc., Y is -CH2-, -CO-, -SO2-, etc., Z is -CO-, -SO2-, etc., and R3 is carbocyclic group, heterocyclic group, hydroxyl, alkoxy or amino, is useful as a controlling agent of the function of CCR4 useful for the prevention or treatment for bronchial asthma, atopic dermatitis, etc.

  以下是该公式表示的脂环杂环化合物或其药用可接受盐： 其中环A是杂环，环B是碳环，杂环等，P1和P2是CH或N，q和r为0至2，X为-NH-，-O-，-CH2-等，Y为-CH2-，-CO-，-SO2-等，Z为-CO-，-SO2-等，R3为碳环基团，杂环基团，羟基，烷氧基或氨基， 可用作CCR4功能的控制剂，用于预防或治疗支气管哮喘，特应性皮炎等。
• Novel pyrazinone derivatives
  申请人：Hayama Takashi

  公开号：US20050176719A1

  公开（公告）日：2005-08-11

  The present invention relates to a compound of the general formula (I): [Ar 1 is aryl fused to the adjacent pyrazinone ring at the 5th and 6th positions, etc., X is CO, etc., Y is CH, etc., Z is CH, etc., V is CH, etc., W n is —(CH 2 ) n — (n is zero to four), R 1 , is H or optionally substituted lower alkyl, etc., R 2 is H, etc., R 3 and R 4 are the same or different and are each H, etc., R 5 and R 6 are the same or different and are each H, hydroxy, etc.] or a pharmaceutically acceptable salt or ester thereof; a pharmaceutical composition, an inhibitor of Cdk4 and/or Cdk6 or an anti-cancer agent, containing the same as an active ingredient; and a process for preparing them.

  本发明涉及一种通式（I）的化合物：[Ar1是与相邻的吡嗪酮环在第5和第6位融合的芳基，等等，X是CO等，Y是CH等，Z是CH等，V是CH等，Wn是-（CH2）n-（n为零到四），R1是H或可选取代的低碳基等，R2是H等，R3和R4相同或不同，分别为H等，R5和R6相同或不同，分别为H、羟基等]或其药学上可接受的盐或酯；一种含有该化合物作为活性成分的药物组合物、Cdk4和/或Cdk6抑制剂或抗癌剂；以及其制备方法。
• Nitrogeneous cyclic ketone derivative, process for producing the same, and use
  申请人：Yamaoka Masayoshi

  公开号：US20050038072A1

  公开（公告）日：2005-02-17

  A novel compound represented by the formula (I): wherein rings A and B each represents an optionally substituted aromatic ring, or rings A and B may be bonded to each other through linking between bonds or substituents thereof to form a ring; ring C represents a nitrogenous saturated heterocycle optionally having one or more substituents besides the oxo (provided that 2,3-dioxopyrrolidine ring is excluded); R 1 represents hydrogen, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group; and indicates a single bond or a double bond. It has high antagonistic activity against a tachykinin receptor, especially an SP receptor.

  一种新的化合物，化学式表示为（I）：其中环A和环B分别代表一个可选取代芳香环，或者环A和环B通过键或它们的取代基之间的连接结合形成一个环；环C代表一个氮饱和杂环，除了氧代（提供2,3-二氧代吡咯烷环除外）之外，还可以选择具有一个或多个取代基；R1代表氢、可选取代的碳氢基团或可选取代的杂环基团；表示单键或双键。它对一种快速激动肽受体，尤其是SP受体具有高拮抗活性。
• Alicyclic Heterocyclic Compound
  申请人：Furukubo Shigeru

  公开号：US20090182140A1

  公开（公告）日：2009-07-16

  An alicyclic heterocyclic compound represented by the following formula or a pharmaceutically acceptable salt thereof: wherein ring A is a heterocyclic ring, ring B is a carbocyclic ring, a heterocyclic ring etc., P 1 and P 2 are CH or N, q and r are 0 to 2, X is —NH—, —O—, —CH 2 —, etc., Y is —CH 2 —, —CO—, —SO 2 —, etc., Z is —CO—, —SO 2 —, etc., and R 3 is carbocyclic group, heterocyclic group, hydroxyl, alkoxy or amino, is useful as a controlling agent of the function of CCR 4 useful for the prevention or treatment for bronchial asthma, atopic dermatitis, etc.

  以下式子所示的脂环杂环化合物或其药学上可接受的盐： 其中环A为杂环，环B为碳环，杂环等，P1和P2为CH或N，q和r为0至2，X为—NH—，—O—，—CH2—等，Y为—CH2—，—CO—，—SO2—等，Z为—CO—，—SO2—等，R3为碳环基团，杂环基团，羟基，烷氧基或氨基，用作CCR4功能调节剂，用于预防或治疗支气管哮喘，特应性皮炎等。
• Cephem compounds, processes for their preparation and pharmaceutical compositions containing them
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0025199A2

  公开（公告）日：1981-03-18

  Cephem compounds of the formula: wherein R1 is amino or a a protected amino group; R2 is cyclo(lower)alkenyl; R3 is carboxy or a protected carboxy group; R'is hydrogen or a group of the formula: -CH2-R4a [wherein R4a is acyloxy, amino (lower) alkylthio, a protected amino(lower) alkylthio group, pyridinium which may have suitable substituent(s) or a heterocyclicthio group which may have suitable substituent(s)], and R5 is hydrogen or lower alkyl, with proviso that R is COO- when R4a is pyridinium which may have suitable substituent(s), and pharmaceutically acceptable salts thereof and process for their preparation, and also a pharmaceutical composition comprising, as an effective ingredient, the above compound in association with a pharmaceutically acceptable, substantially nontoxic carrier or excipient. The invention also relates to the starting compounds and their preparation.

  式中的 Cephem 化合物： 其中 R1 是氨基或受保护的氨基； R2 是环（低级）烯基 R3 是羧基或受保护的羧基； R'是氢或一个式中的基团：-CH2-R4a [其中 R4a 是酰氧基、氨基（低级）烷硫基、受保护的氨基（低级）烷硫基、可有适当取代基的吡啶鎓或可有适当取代基的杂环鎓基团]，R5 是氢或低级烷基，但当 R4a 是可有适当取代基的吡啶鎓时，R 是 COO-、和其药学上可接受的盐及其制备工艺，以及一种药物组合物，其有效成分包括上述化合物与药学上可接受的、基本上无毒的载体或赋形剂。本发明还涉及起始化合物 及其制备方法。